Will IL28B Polymorphisms Remain Relevant to Direct-Acting Antiviral Treatment Paradigms?

Antiviral Therapy - United Kingdom
doi 10.3851/imp2427
Full Text
Abstract

Available in full text

Date
Authors
Publisher

International Medical Press

Related search

Oral Direct-Acting Antiviral Therapy for Hepatitis C

Journal of Antivirals & Antiretrovirals
2012English

Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy

Clinical Liver Disease
Hepatology
2019English

Response To: Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antiviral Drug

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2016English

Relapse or Reinfection After Failing Hepatitis C Direct Acting Antiviral Treatment: Unravelled by Phylogenetic Analysis

PLoS ONE
Multidisciplinary
2018English

Treatment of the Chronic Hepatitis C Complicated by Mixed Cryoglobulinemia With Direct-Acting Antiviral Agents

Jurnal Infektologii
Infectious Diseases
2018English

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents

PLoS Pathogens
ImmunologyMolecular BiologyVirologyMicrobiologyParasitologyGenetics
2014English

Changes in Hepatic Fibrosis Stages After Achieving SVR Following Direct Acting Antiviral Treatment: A Prospective Study

GastroHep
2020English

No Evidence for Higher Rates of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment: A Meta-Analysis

Hepatoma Research
2019English

Hepatocellular Carcinoma Mechanisms Associated With Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

Journal of Hepatocellular Carcinoma
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy